Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 18, 2011, Pages 7505-7510

  Chung, Amy W ^a   Isitman, Gamze ^a   Navis, Marjon ^a   Kramski, Marit ^a   Center, Rob J ^a   Kent, Stephen J ^a,b,c   Stratov, Ivan ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Sexual Health Physician at Melbourne Sexual Health Clinic   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

Natural killer cells; Neutralizing antibody; Viral evolution

Indexed keywords

ANTIBODY; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ADULT; AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ESCAPE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS STRAIN;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BASE SEQUENCE; EPITOPE MAPPING; EPITOPES; FLOW CYTOMETRY; GENE PRODUCTS, ENV; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PLASMIDS; SEQUENCE ANALYSIS, DNA;

EID: 79956335022     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1016048108     Document Type: Article

References (26)

1. Rerks-Ngarm S, et al.; MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209-2220.
2. Karnasuta C, et al.; Thai AIDS Vaccine Evaluation Group, Thailand (2005) Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-2529.
3. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I (2008) The utility of ADCC responses in HIV infection. Curr HIV Res 6:515-519.
4. Hessell AJ, et al. (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104. (Pubitemid 47373775)
5. Florese RH, et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182:3718-3727.
6. Gómez-Román VR, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174:2185-2189. (Pubitemid 40223963)
7. Gómez-Román VR, et al. (2006) A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 308:53-67. (Pubitemid 43107954)
8. Dinges WL, et al. (2010) Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol 84:4461-4468.
9. Nandi A, et al.; NIAID Center for HIV/AIDS Vaccine Immunology (2010) Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396:339-348.
10. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I (2009) Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 182:1202-1210.
11. Stratov I, Chung A, Kent SJ (2008) Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82:5450-5459. (Pubitemid 351705252)
12. Isitman G, Navis M, Stratov I, Kent SJ (2010) Purification and Evaluation of HIV-specific ADCC Antibodies, Abstract 329 (Conference on Retroviruses and Opportunistic Infections, San Francisco).
13. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 100:4144-4149. (Pubitemid 36418171)
14. Phillips RE, et al. (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459. (Pubitemid 21896855)
15. Fernandez CS, et al. (2005) Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79:5721-5731. (Pubitemid 40548241)
16. Leslie AJ, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10:282-289. (Pubitemid 38667619)
17. Goonetilleke N, et al.; CHAVI Clinical Core B (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206:1253-1272.
18. Mavilio D, et al. (2005) Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 102:2886-2891. (Pubitemid 40299886)
19. Goepfert PA, et al. (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 205:1009-1017. (Pubitemid 351679677)
20. Troyer RM, et al. (2009) Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog 5:e1000365.
21. Peut V, Kent SJ (2007) Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol 81:13125-13134. (Pubitemid 350156951)
22. Peut V, Kent SJ (2009) Substantial envelope-specific CD8 T-cell immunity fails to control SIV disease. Virology 384:21-27.
23. Fernandez CS, et al. (2007) Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol 81:4137-4144. (Pubitemid 46586908)
24. Stratov I, Dale CJ, Chea S, McCluskey J, Kent SJ (2005) Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 79: 7728-7737. (Pubitemid 40756806)
25. Center RJ, et al. (2009) Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 27:6605-6612.
26. Peut V, et al. (2009) Balancing reversion of cytotoxic T-lymphocyte and neutralizing antibody escape mutations within human immunodeficiency virus type 1 Env upon transmission. J Virol 83:8986-8992.